De Gaulle Fleurance advises AlphaRose Therapeutics on the acquisition of Alpha Anomeric SA
De Gaulle Fleurance assisted US company AlphaRose Therapeutics with its first acquisition in Europe, that of biotech Alpha Anomeric SA.
Based in Austin, Texas, AlphaRose Therapeutics was founded in 2024 by Casey McPherson. It develops and markets treatments for neurogenetic developmental diseases.
For its part, Alpha Anomeric is a French company, founded in 2018, that has developed a novel proprietary oligonucleotide chemistry platform (abcDNA), a patented technology that may be exploited by the US company.
AlphaRose Therapeutics was advised in the United States by Faber Law (Ken Itrato, Maria Bergenhem), and in France by Jean-Christophe Amy and Jean-Marie Job, partners, and Charlotte Hébert-Salomon, senior counsel at De Gaulle Fleurance.
"We are delighted to have supported AlphaRose Therapeutics in its external growth project in Europe,"
"This acquisition of Alpha Anomeric will contribute to the development of new models for the rapid development of treatments for rare diseases”.
Press contacts :
Constance Baudry, +33 (0)6 82 43 69 62,
constance.baudry@agence-constance.fr
Sarah Maouchi, +33 (0)7 57 76 83 97,
sarah.maouchi@agence-constance.fr
